Atossa Genetics, Inc., a private company, is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. SNNLive met with Dr. Steven Quay, Chairman of the Board and CEO of Atossa Genetics at the Biotech Showcase 2012 in San Francisco, CA. Dr. Quay was pleased to announce that the company, “just launched two products: one for screening for women at high risk for breast cancer, and the other a test for women who already have breast cancer looking for circulating tumor cells. Now that we have launched the product we are starting to get samples in the laboratory and generating some revenue.”
Using 5 biomarkers, the test, “takes a small sample from the nipple of a non-lactating woman, and we look for early changes, changes that can happen before you get breast cancer. There’s about an 8 year window of changes that occur before breast cancer actually arrives, and we want to find the women that have these changes to see what happens.” Atossa Genetics also has a simple blood test that, “finds the 5 or 10 cancer cells that are circulating, and we interrogate them to see what they are sensitive too. For the first time, we are the only company that can say, you do have a recurrence of breast cancer, but its sensitive to tamoxifen or herceptin or certain types of drugs.”
Dr. Quay concludes by stating the company, “intends to expand to the entire nation this year.” Atossa Genetics’ products are currently in use in New York, Florida, Texas, Oklahoma, California and Washington. For more information about Atossa Genetics, check out their website, and you can follow them on Twitter @AtossaGenetics. Atossa Genetics will also be featured in the next issue of the Micro Cap Review Magazine. SNNLive welcomes Dr. Steven Quay, Chairman of the Board and CEO of Atossa Genetics, Inc.
Micro-Cap Review Latest Issue
Cavaet Emptor or Buyer Beware by SNN Inc. CEO Sheldon “Shelly” Kraft
Check out the book "Caveat Emptor" written by CEO Sheldon Kraft, click on the image to view a preview and the full book can be purchased for $15.95.
There are some best practices and good hints on what to look out for in today’s volatile markets.